HighPoint Blog

Since the infancy of specialty drugs on the market in the 1990s, specialty pharmaceuticals have attracted attention in part due to the complex supply chain and high-touch requirements before, during and after administration, according to the National Pharmaceutical Services (NPS), 2018.

Read More

A controversial new health insurance plan benefit design option has recently been introduced by insurers, which will further shift specialty drug costs away from payers and onto drug manufacturers and consumers. Known as copay accumulator adjustments, the true price of this new approach to copay assistance programs may reveal as reduced prescription volumes, and therefore, revenue, for...

Read More

Recent Posts